LSE:AZNPharmaceuticals
FDA TRUQAP Approval Highlights AstraZeneca’s Precision Oncology And Valuation Gap
US FDA approved TRUQAP (capivasertib) in combination with abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer.
TRUQAP is the first and only targeted treatment option for this specific PTEN-deficient metastatic prostate cancer setting.
The approval is supported by the CAPItello-281 Phase III trial, which reported a reduction in the risk of disease progression or death.
A companion diagnostic for PTEN...